Document is current
Any future updates will be listed below
-
Authors
Jansen, Mylène P. https://orcid.org/0000-0003-1929-6350
Turmezei, Tom D.
Dattani, Kishan
Kessler, Dimitri A.
Mastbergen, Simon C.
Kloppenburg, Margreet
Blanco, Francisco J.
Haugen, Ida K.
Berenbaum, Francis
Wirth, Wolfgang
Eckstein, Felix
Roemer, Frank W.
MacKay, James W.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115770)
- License Information
-
More Information
Article History
Received: 16 January 2025
Revised: 3 March 2025
Accepted: 7 March 2025
First Online: 21 March 2025
Declarations
:
: The study was approved by the regional ethical committees and Institutional Review Boards (UMC Utrecht, Leiden University Medical Center, Complejo Hospitalario Universitario de A Coruña, AP-HP Saint-Antoine Hospital, and Diakonhjemmet Hospital) and was conducted in compliance with the study protocol, Good Clinical Practice (GCP), the Declaration of Helsinki, and the applicable ethical and legal regulatory requirements. All participants have received oral and written information and provided written informed consent. The study was registered under clinicaltrials.gov nr: NCT03883568.
: T.D. Turmezei: director and shareholder of KNEE3D Ltd, consulting fees from GSK plc and CurveBeamAI, royalties from Elsevier, scientific advisory board for Chondrometrics GmbH, editorial board for Osteoarthritis Imaging.M. Kloppenburg: consulting fees from Pfizer, CHDR, Novartis, UCB, GSK, and Peptinov, all paid to the institution. Royalties from Wolters-Kluwer and Springer Verlag, all paid to the institution.F.J. Blanco: funding from Gedeon Richter Plc., Bristol-Myers Squibb International Corporation (BMSIC); Sun Pharma Global FZE; Celgene Corporation; Janssen Cilag International N.V; Janssen Research & Development; Viela Bio, Inc.; Astrazeneca AB; UCB BIOSCIENCES GMBH; UCB BIOPHARMA SPRL; AbbVie Deutschland GmbH & Co.KG; Merck KGaA; Amgen, Inc.; Novartis Farmacéutica, S.A.; Boehringer Ingelheim España, S.A; CSL Behring; LLC; Glaxosmithkline Research & Development Limited, Pfizer Inc; Lilly S.A.; Corbus Pharmaceuticals Inc.; Biohope Scientific Solutions for Human Health S.L.; Centrexion Therapeutics Corp.; Sanofi; TEDEC-MEIJI FARMA S.A.; KiniksaPharmaceuticals, Ltd. Grunenthal.I.K. Haugen: research grant (ADVANCE) from Pfizer (payment to institution) and personal fees from Abbvie, Novartis, Grünenthal, and GSK, outside of the submitted work.F. Berenbaum: consulting fees from Grunenthal, GSK, Eli Lilly, Novartis, Pfizer, Servier, and 4P Pharma; honoraria from Viatris, Pfizer, and Zoetis; travel support from Nordic Pharma; holds patents related to 4Moving Biotech; serves on advisory boards for AstraZeneca, Sun Pharma, and Nordic Bioscience; and holds stock in 4P Pharma and 4Moving Biotech. CMO and co-founder of 4Moving Biotech.W. Wirth: employee and shareholder of Chondrometrics GmbH.F. Eckstein: CEO and shareholder of Chondrometrics GmbH; received personal fees from Formation Bio, Peptinov, 4P Pharma, Novartis, and Kolon TissueGene; and grants from PMU, BMBF, EU, NIH, FNIH, Merck, Galapagos NV, Novartis, Kolon TissueGene, CALIBR, ICM, Bioclinica/Clario, and the Universities of Erlangen, Sydney, Basel, Western Ontario, Stanford, Imperial College, Aachen and Utrecht.F.W. Roemer: shareholder of Boston Imaging Core Lab (BICL), LLC, and consultant to Grünenthal GmbH. Editor in Chief Osteoarthritis Imaging.J.W. MacKay: employee and shareholder of AstraZeneca.The authors declare that they have no conflict of interest.
